Octave Announces Publication of Analytical Validation Study Results in Nature Communications More

Our Science

Powerful innovation to transform MS

We're committed to rigorous and ongoing evaluation.

Browse our latest publications below.

Category

1 2 … 9

Visualizing the topographical model of multiple sclerosis using novel 3D rendering of quantified MRI

Research Presented at ECTRIMS 2024

Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies

Research Presented at ECTRIMS 2024

Real-World Utilization of a Multi-Proteomic, Serum-Based Assay for Assessing Response to Therapy in Persons with Multiple Sclerosis

Research Presented at ECTRIMS 2024

Safety and effectiveness of cladribine tablets after treatment with natalizumab (CLADRINA trial) – 2 year results

Research Presented at ECTRIMS 2024

Impact of MS Imaging Analytics on MRI Report Findings

Research Presented at ECTRIMS 2024

Comparing Neuroradiologist Qualitative Rating of Atrophy to Normative Brain Volume Measures

Research Presented at CMSC 2024

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS: A Case Study

Research Presented at CMSC 2024

Novel Visualization of the Topographical Model of Multiple Sclerosis Using 3D Rendering of Quantified MRI

Research Presented at AAN 2024

Predictive Utility of Serum Protein Biomarkers from the Octave MSDA Panel for Optic Neuritis Events in People with Multiple Sclerosis

Research Presented at AAN 2024

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS – A Case Study

Research Presented at ACTRIMS 2024 - February 29 - March 1